Mankind Pharma to Acquire Bharat Serums from Advent International
Mankind Pharma reported a turnover of Rs 1,723.5 crore in 2023-24.
image for illustrative purpose
On Thursday, Mankind Pharma Limited announced that it has agreed to acquire a 100% stake in Bharat Serums and Vaccines (BSV) Limited from Advent International for approximately Rs 13,630 crore, subject to closing adjustments.
This acquisition establishes Mankind Pharma as a frontrunner in the Indian market for women's health and fertility medications, while also providing access to high-barrier products in critical care through advanced research and development platforms.
Mankind Pharma, the fourth-largest pharmaceutical company in India by market share, reported a turnover of Rs 1,723.5 crore in 2023-24.
BSV specialises in women’s health and critical care and is known for its strong R&D capabilities and robust branded product portfolio, including recombinant and niche biologic products.
The acquisition details were confirmed in a post-market regulatory filing, emphasising the strategic benefits and enhanced market position for Mankind Pharma.
